Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07176780

Effect of Semiconductor Embedded Wearable Sleeve on Treatment of Primary Dysmenorrhea Symptoms

This study is looking to test a non-compressive semiconductor embedded body sleeve for treatment of primary dysmenorrhea symptoms. Dysmenorrhea is the lower abdominal pain (sometimes referred to as "cramping") experienced during menstruation (monthly "period"), affecting up to 94% of people aged from 10-20 years old. The semiconductor embedded fabric increases blood circulation through activation of the embedded elements with body heat while worn and releases energy waves as well as negative ions. This energy has an effect inside the body that increases oxygen and nutrient flow to tissues, and can help to decrease pain and inflammation. This study is testing this technology to see if it can be used as a non-pharmacological treatment for menstrual cramping.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Self-reported primary dysmenorrhea during past three menstrual cycles
  • Age 18-45 inclusive at the time of consent
  • Self-reported typical primary dysmenorrhea symptom pain greater than 4 on a 1-10 visual analog scale (VAS)
  • History of regular menstrual cycles with a usual length of 21 to 35 days
  • Willing and able to provide informed consent and adhere to study requirements

Exclusion criteria

  • History of neurological conditions, including multiple sclerosis or Parkinson's disease
  • Secondary dysmenorrhea including confirmed or suspected endometriosis or fibroids or intrauterine device
  • Self-reported size not available in study device
  • Pregnant or planning to become pregnant during the study
  • Have within the past six months of enrollment, or are planning to in the next six months, start or discontinue any of the following contraceptive methods:
  • intrauterine device
  • oral contraceptives,
  • contraceptive patch,
  • implant (Nexplanon),
  • shot (Depo-Provera),
  • vaginal ring
  • Chronic pain conditions unrelated to primary dysmenorrhea
  • Auto-immune or auto-inflammatory diseases
  • Has used within the last 90 days or is planning to use nicotine-containing products
  • History of metabolic disorders
  • Active infection (local or systemic) that, in the opinion of the investigator, would prevent usage of the device
  • In the opinion of the investigator, any other criteria or condition that could increase the risk associated with study participation or study treatment or could interfere with the interpretation of study results
  • Have taken any investigational drug or used any investigational device within the 30 days prior to consent.

Treatment and study plan

Semiconductor embedded body sleeve

Device

The active device contains semiconductors embedded into the body sleeve fabric

Placebo Non-Compressive Body Sleeve

Device

Identical body sleeve absent of semiconductors

Primary outcomes

  1. Participant-Reported Changes in Pain

    Time frame: 6 months

    Reduction in menstrual symptom severity as determined by the Visual Analog Scale (VAS) compared to placebo group:

    Visual Analog Scale for Pain (VAS) Minimum value: 0 (no pain) Maximum value: 10 (worst possible pain)

Secondary outcomes

  1. Participant-Reported Changes in Quality of Life

    Time frame: 6 months

    Improvement in health-related quality of life as determined by the Short Form quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-SF) compared to placebo group.

    Q-LES-Q-SF:

    Lowest score: 14 (indicating very poor quality of life) Highest score: 70 (indicating very good quality of life)

  2. Changes in oral medication intake compared to placebo group

    Time frame: 6 months

    As measured by collecting concomitant medication information at baseline and changes throughout participation in the study.

  3. Changes in Participant Pain Score (SF-MPQ-2)

    Time frame: 6 months

    Changes in participant menstrual pain as determined by menstrual pain questionnaire, Short Form McGill Pain Questionnaire (SF-MPQ-2), compared to placebo group.

    SF-MPQ-2:

    Lowest score: 0 (no pain) Highest score: 10 (worst possible pain)

  4. Changes in participant function in daily life

    Time frame: 6 months

    Changes in participant function/distress as determined by Menstrual Distress Questionnaire (MEDI-Q), compared to placebo group.

    MEDI-Q:

    Lowest score: 0 (no distress) Highest score: 5 (very much distress)

  5. Changes in menstrual symptom duration

    Time frame: 6 months

    Changes in menstrual symptom duration compared to placebo group as reported by participants at each menstrual cycle.

Study contacts

Contact information is provided by the study sponsor or research team.

UC Davis Health Ob/Gyn Research

CONTACT

[email protected]

916-734-6846

Sponsors and collaborators

Lead sponsor

University of California, Davis

Other

Collaborators

  • INCREDIWEAR HOLDINGS, INC.

Registry information

Official study title

Effect of Semiconductor Embedded Wearable Sleeve on the Treatment and Mitigation of Primary Dysmenorrhea Symptoms: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Sep 16, 2025
Registry last updated
Jun 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.